Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

alnylam pharmaceuticals inc. - ALNY

ALNY

Close Chg Chg %
328.16 -10.80 -3.29%

Closed Market

317.36

-10.80 (3.29%)

Volume: 815.90K

Last Updated:

Mar 27, 2026, 4:00 PM EDT

Trade Now

Company Overview: alnylam pharmaceuticals inc. - ALNY

ALNY Key Data

Open

$327.10

 Day Range

316.85 - 329.69

52 Week Range

205.87 - 495.55

 Market Cap

$43.52B

Shares Outstanding

132.62M

 Public Float

131.46M

Beta

0.36

 Rev. Per Employee

N/A

P/E Ratio

140.87

 EPS

$2.37

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.17M

  

ALNY Performance

1 Week
 
 5.12%
 
1 Month
 
 -1.43%
 
3 Months
 
 -18.08%
 
1 Year
 
 22.24%
 
5 Years
 
 140.85%
 

ALNY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 28
Full Ratings ➔

About alnylam pharmaceuticals inc. - ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

ALNY At a Glance

Alnylam Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge, Massachusetts 02142
Phone 1-617-551-8200 Revenue 3.71B
Industry Pharmaceuticals: Major Net Income 313.75M
Sector Health Technology 2025 Sales Growth 65.193%
Fiscal Year-end 12 / 2026 Employees 2,500
View SEC Filings

ALNY Valuation

P/E Current 141.103
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 170.702
Price to Sales Ratio 14.421
Price to Book Ratio 66.702
Price to Cash Flow Ratio 102.19
Enterprise Value to EBITDA 96.22
Enterprise Value to Sales 14.437
Total Debt to Enterprise Value 0.055

ALNY Efficiency

Revenue/Employee 1,485,574.80
Income Per Employee 125,498.80
Receivables Turnover 4.776
Total Asset Turnover 0.796

ALNY Liquidity

Current Ratio 2.762
Quick Ratio 2.706
Cash Ratio 1.983

ALNY Profitability

Gross Margin 81.64
Operating Margin 13.505
Pretax Margin 8.701
Net Margin 8.448
Return on Assets 6.727
Return on Equity 73.283
Return on Total Capital 8.349
Return on Invested Capital 10.206

ALNY Capital Structure

Total Debt to Total Equity 376.19
Total Debt to Total Capital 79.00
Total Debt to Total Assets 59.075
Long-Term Debt to Equity 342.536
Long-Term Debt to Total Capital 71.933
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Alnylam Pharmaceuticals Inc. - ALNY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
1.04B 1.83B 2.25B 3.71B
Sales Growth
+22.88% +76.23% +22.97% +65.19%
Cost of Goods Sold (COGS) incl D&A
168.82M 310.41M 323.37M 681.87M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
44.47M 54.05M 56.67M 55.66M
Depreciation
39.10M 51.60M 55.10M 54.80M
Amortization of Intangibles
5.37M 2.45M 1.57M 858.00K
COGS Growth
+20.46% +83.87% +4.18% +110.86%
Gross Income
868.60M 1.52B 1.92B 3.03B
Gross Income Growth
+23.36% +74.75% +26.81% +57.52%
Gross Profit Margin
+83.73% +83.02% +85.62% +81.64%
2022 2023 2024 2025 5-year trend
SG&A Expense
1.65B 1.80B 2.10B 2.53B
Research & Development
883.01M 1.00B 1.13B 1.32B
Other SG&A
770.66M 795.65M 975.53M 1.21B
SGA Growth
+17.05% +8.85% +16.76% +20.40%
Other Operating Expense
- - - -
-
Unusual Expense
171.25M 91.00M 170.77M 42.47M
EBIT after Unusual Expense
(956.32M) (373.17M) (347.65M) 459.10M
Non Operating Income/Expense
(14.71M) 60.88M 112.14M 116.67M
Non-Operating Interest Income
24.81M 95.56M 121.99M 111.47M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
155.97M 121.22M 141.86M 252.63M
Interest Expense Growth
+9.05% -22.28% +17.02% +78.08%
Gross Interest Expense
155.97M 121.22M 141.86M 252.63M
Interest Capitalized
- - - -
-
Pretax Income
(1.13B) (433.52M) (377.38M) 323.15M
Pretax Income Growth
-32.25% +61.53% +12.95% +185.63%
Pretax Margin
-108.63% -23.71% -16.79% +8.70%
Income Tax
4.16M 6.72M (99.22M) 9.40M
Income Tax - Current - Domestic
- 4.02M 1.60M 1.93M
Income Tax - Current - Foreign
5.60M 3.42M 5.94M 9.67M
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
(1.43M) (713.00K) (106.76M) (2.20M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(1.13B) (440.24M) (278.16M) 313.75M
Minority Interest Expense
- - - -
-
Net Income
(1.13B) (440.24M) (278.16M) 313.75M
Net Income Growth
-32.64% +61.08% +36.82% +212.79%
Net Margin Growth
-109.04% -24.08% -12.37% +8.45%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(1.13B) (440.24M) (278.16M) 313.75M
Preferred Dividends
- - - -
-
Net Income Available to Common
(1.13B) (440.24M) (278.16M) 313.75M
EPS (Basic)
-9.2955 -3.5246 -2.179 2.3949
EPS (Basic) Growth
-29.11% +62.08% +38.18% +209.91%
Basic Shares Outstanding
121.69M 124.91M 127.65M 131.00M
EPS (Diluted)
-9.2955 -3.5246 -2.179 2.3295
EPS (Diluted) Growth
-29.11% +62.08% +38.18% +206.91%
Diluted Shares Outstanding
121.69M 124.91M 127.65M 134.68M
EBITDA
(740.60M) (228.12M) (120.22M) 557.24M
EBITDA Growth
-12.03% +69.20% +47.30% +563.53%
EBITDA Margin
-71.39% -12.48% -5.35% +15.00%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 450.435
Number of Ratings 28 Current Quarters Estimate 0.932
FY Report Date 03 / 2026 Current Year's Estimate 6.55
Last Quarter’s Earnings 0.82 Median PE on CY Estimate N/A
Year Ago Earnings 2.33 Next Fiscal Year Estimate 10.511
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 19 19 21 18
Mean Estimate 0.93 1.43 6.55 10.51
High Estimates 1.65 2.15 8.79 14.99
Low Estimate 0.04 0.67 3.56 6.86
Coefficient of Variance 41.17 28.48 21.39 22.71

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 19 17
OVERWEIGHT 4 4 4
HOLD 8 7 9
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Alnylam Pharmaceuticals Inc. - ALNY

Date Name Shares Transaction Value
Mar 3, 2026 Jeffrey V. Poulton EVP, Chief Financial Officer 61,710 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2026 Pushkal P. Garg EVP Chief R&D N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2026 Pushkal P. Garg EVP Chief R&D 22,269 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $332.48 per share 7,403,997.12
Mar 3, 2026 Tolga Tanguler EVP, Chief Commercial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2026 Tolga Tanguler EVP, Chief Commercial Officer 33,435 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2026 Pushkal P. Garg EVP Chief R&D 24,370 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $330.73 per share 8,059,890.10
Mar 3, 2026 Pushkal P. Garg EVP Chief R&D 22,129 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $334.39 per share 7,399,716.31
Mar 3, 2026 Pushkal P. Garg EVP Chief R&D 26,629 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $328.92 per share 8,758,810.68
Mar 3, 2026 Pushkal P. Garg EVP Chief R&D 23,211 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $331.49 per share 7,694,214.39
Mar 3, 2026 Yvonne L. Greenstreet Chief Executive Officer; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2026 Yvonne L. Greenstreet Chief Executive Officer; Director 91,583 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2026 Jeffrey V. Poulton EVP, Chief Financial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 3, 2026 Pushkal P. Garg EVP Chief R&D 26,756 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 26, 2026 Kevin Fitzgerald CSO & EVP, Head of Research 21,422 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Michael W. Bonney Director 21,323 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $280.03 per share 5,971,079.69
May 20, 2025 Michael W. Bonney Director 18,421 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $282.81 per share 5,209,643.01
May 20, 2025 Michael W. Bonney Director 20,149 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $282.03 per share 5,682,622.47
May 20, 2025 Michael W. Bonney Director 20,951 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $281.1 per share 5,889,326.10
May 20, 2025 Michael W. Bonney Director 25,440 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $273.16 per share 6,949,190.40
May 20, 2025 Michael W. Bonney Director 26,100 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $271.68 per share 7,090,848.00

Alnylam Pharmaceuticals Inc. in the News